| Not Yet Recruiting | A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophage NCT07517211 | Jonsson Comprehensive Cancer Center | — |
| Not Yet Recruiting | Individually Tailored, Supervised, Remote Exercise Intervention to Improve Physical Function for Stage I-III G NCT07439484 | Jonsson Comprehensive Cancer Center | N/A |
| Withdrawn | Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers NCT05296005 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Enrolling By Invitation | Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for the Treatment of Patients With Gas NCT07139951 | Mayo Clinic | Phase 2 |
| Recruiting | Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in P NCT06364410 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, NCT05911243 | University of Washington | N/A |
| Recruiting | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial NCT06203600 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Active Not Recruiting | Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastr NCT05836584 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastati NCT05677490 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Recruiting | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381 | Mayo Clinic | Phase 1 / Phase 2 |
| Recruiting | Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adeno NCT05041153 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or C NCT04491942 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or NCT04535401 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tu NCT04704661 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Adv NCT04660760 | Academic and Community Cancer Research United | Phase 2 |
| Recruiting | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations NCT04550494 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gast NCT03641313 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma NCT04111172 | Thomas Jefferson University | Phase 2 |
| Active Not Recruiting | Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma NCT04523818 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Real-Time Monitoring of Chemotherapy Side-Effects in Patients With Gastrointestinal Cancers, RT-CAMSS Study NCT04449679 | Thomas Jefferson University | N/A |
| Active Not Recruiting | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors NCT04007744 | Mayo Clinic | Phase 1 |
| Completed | Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes NCT04501913 | City of Hope Medical Center | — |
| Active Not Recruiting | Early Recovery After Surgery Protocol in Improving Quality of Life in Participants With Stage 0-IIIC Gastric C NCT03997162 | City of Hope Medical Center | — |
| Completed | Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma NCT03395847 | M.D. Anderson Cancer Center | EARLY_Phase 1 |